-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: BIO Investor Forum
Peptimmune Collaborates with Walter Reed on Dengue Virus Vaccine
Peptimmune, Inc. has formed a collaboration with the Walter Reed Army Institute of Research and Naval Medical Research Center for the development of Dengue vaccines and point-of-care diagnostics. The goal of the R&D project is to evaluate the company’s Directed Expansion of Epitope Permutations (DEEP) technology to potentially design DENV-specific peptide copolymers. The results of this effort have the potential to provide insights into dengue immunity and advance the development of a protective vaccine.
Idera Pharmaceuticals Phase 2 Results for Renal Cell Carcinoma Therapy
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced final data results from a clinical trial evaluating IMO-2055, a monotherapy in patients with Renal Cell Carcinoma. Progression-free survival medians for treatment-naïve patients were 4.5 months at 0.16 mg/kg/week and 1.9 months at 0.64 mg/kg/week. The most common adverse events included fatigue, nausea, chills, headache, and pyrexia.
Cleveland BioLabs Receives Additional Funding for Radiation Project
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced an additional $2.3 million in funding for a $13.3 million contract with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (DHHS) for the development of Radiation Countermeasure Protectan CBLB502. In addition, BARDA increased the first milestone-based option from $4.0 million to $6.3 million, increasing the total contract value including all milestone-based options from $13.3 million to $15.6 million over the Read More >
Dendreon’s PROVENGE making regulatory and commercialization progress
Dendreon Corporation (Nasdaq: DNDN) today reported regulatory and commercialization progress for PROVENGE® (sipuleucel-T), the company’s investigational prostate cancer product. Dendreon expects to prepare for commercialization of PROVENGE by the middle of next year. Dendreon further plans to initiate a clinical trial of NEUVENGE™ (lapuleucel-T) to treat bladder cancer, and potentially, breast and colorectal cancers. At today’s analyst event, the company also reported the expansion of its manufacturing facility in New Jersey and the addition of Read More >
Inovio CEO Speaks at MIT Conference
Dr. J. Joseph Kim, CEO of Inovio Biomedical Corporation (NYSE Amex: INO), presented keynote remarks on universal DNA vaccines to prevent and treat infectious diseases (such as Influenza) at MIT’s Emerging Technologies Conference. Dr. Kim’s speech focused on the advantages of DNA vaccines versus traditional therapies, which includes speed of development, ease of manufacture, and broader immune responses, as well as the “designer” nature of Inovio’s vaccine approach. The conference took place this week in Read More >
